open access

Vol 1, No 1 (2005)
Review paper
Published online: 2005-05-17
Get Citation

Clinical effects of multidrug resistance in neoplasms

Katarzyna Lenart, Anna Szyda, Marek Kiełbasiński, Danuta Duś, Maria Podolak-Dawidziak
Onkol. Prak. Klin 2005;1(1):18-26.

open access

Vol 1, No 1 (2005)
REVIEW ARTICLES
Published online: 2005-05-17

Abstract

Resistance to chemotherapy remains a major cause of the systemic anti-cancer treatment failure. The best known mechanism is often attributed to the function of drug transporter proteins in the plasma membrane, which actively remove drugs from neoplastic cells. Abnormal overexpression of these proteins is the most frequently described factor connected with cytostatics resistance.
Among cellular transporter proteins the most important role plays glicoprotein P (Pgp). Increased level of this protein is considered as a poor prognostic factor both, in leukaemias and in many solid tumors. Clinical significance of other multidrug resistance proteins (MRP1, BCRP and LRP) remains subject of intensive studies.
In experimental models and clinical trials different strategies are used to limit Pgp expression. Introduction of the second and third generation of Pgp blockers is a source of hope for the reversion of multidrug resistance, especially in lymphoid and blood neoplastic disorders.

Abstract

Resistance to chemotherapy remains a major cause of the systemic anti-cancer treatment failure. The best known mechanism is often attributed to the function of drug transporter proteins in the plasma membrane, which actively remove drugs from neoplastic cells. Abnormal overexpression of these proteins is the most frequently described factor connected with cytostatics resistance.
Among cellular transporter proteins the most important role plays glicoprotein P (Pgp). Increased level of this protein is considered as a poor prognostic factor both, in leukaemias and in many solid tumors. Clinical significance of other multidrug resistance proteins (MRP1, BCRP and LRP) remains subject of intensive studies.
In experimental models and clinical trials different strategies are used to limit Pgp expression. Introduction of the second and third generation of Pgp blockers is a source of hope for the reversion of multidrug resistance, especially in lymphoid and blood neoplastic disorders.
Get Citation

Keywords

multidrug resistance proteins; solid tumors; lymphoid and blood neoplastic disorders; multidrug resistance proteins inhibitors

About this article
Title

Clinical effects of multidrug resistance in neoplasms

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 1 (2005)

Article type

Review paper

Pages

18-26

Published online

2005-05-17

Bibliographic record

Onkol. Prak. Klin 2005;1(1):18-26.

Keywords

multidrug resistance proteins
solid tumors
lymphoid and blood neoplastic disorders
multidrug resistance proteins inhibitors

Authors

Katarzyna Lenart
Anna Szyda
Marek Kiełbasiński
Danuta Duś
Maria Podolak-Dawidziak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl